Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Sanofi's Acquisition of Vicebio: Sanofi SA has agreed to acquire Vicebio Ltd for $1.15 billion, enhancing its vaccine portfolio with an early-stage combination vaccine candidate for RSV and hMPV, utilizing Vicebio’s 'Molecular Clamp' technology for improved vaccine development and distribution.
Impact on Respiratory Vaccines: This acquisition reinforces Sanofi's commitment to respiratory vaccines, complementing its existing offerings and allowing for easier manufacturing and distribution of liquid vaccines, while also not significantly impacting the company's financial guidance for 2025.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 99.67 USD with a low forecast of 95.00 USD and a high forecast of 103.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.990
Low
95.00
Averages
99.67
High
103.00
Current: 93.990
Low
95.00
Averages
99.67
High
103.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
